Our congratulations to a former intern
Posted 3 March 2022 BioMelbourne Network is fortunate to work with some passionate and capable biomedical students who join our team as interns. These interns provide much needed assistance to the organisation, while they get the opportunity to…
BioMelbourne Network Podcast
Last updated: 16 November 2022 Want to collaborate on a podcast? Reach out to us now! Episode 1: Special Visa Schemes – The Global Talent Program and Victorian State Visa Nomination Program Australia wants to attract talented people…
Stable Cell Line for Production of PAT-DX3 Established
Posted: 2 March 2022 BioMelbourne Network Member Patrys Limited, a therapeutic antibody development company, is pleased to announce it has identified and selected an optimised stable cell line for production of its full-sized IgG deoxymab, PAT-DX3. This allows…
Andrew Wear appointed to BioMelbourne Network Board of Directors
Posted: 25 February 2022 BioMelbourne Network is excited to announce the appointment of Andrew Wear as a Director on its Board of Directors as of February 2022. “I’m really excited to be joining the board. Melbourne has genuinely…
ENA Respiratory and COPD Foundation to Develop Pan-Antiviral Nasal Spray
Posted: 24 February 2022 ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections, including COVID-19 in populations at-risk of complications, and the COPD Foundation, a…
AusBiotech greets the patent box legislation
Posted: 23 February 2022 AusBiotech has welcomed the patent box legislation that was introduced to the Australian Parliament on 10 February – to provide a tax incentive for Australian medical innovations. AusBiotech CEO, Lorraine Chiroiu, said, “AusBiotech notes…
AMP945 Improves Survival in Human Pancreatic Cancer Model
Posted: 23 February 2022 AMP945 improves effectiveness of current standard of care in an animal model using human pancreatic cancer cells; Addition of AMP945 pre-treatment to gemcitabine/Abraxane® chemotherapy regimen increased survival by 33%; Confirmation in second animal model…
St Vincent’s Hospital Melbourne delivers half a million COVID-19 vaccinations
Posted: 10 February 2022 St Vincent’s Hospital Melbourne has now administered more than half a million COVID-19 vaccination doses across its vaccination programs with support from its newly-skilled workforce who have responded to the call to vaccinate and…
Tessara Therapeutics positions for growth with major appointments to management team
Posted: 10 February 2022 Tessara Therapeutics, an Australian biotechnology company developing synthetic human brain micro-tissues as drug screening and neuro-regenerative medicine platforms, has accelerated its growth and cemented its future with a series of significant senior appointments as…
Planet Innovation and Lumos Diagnostics collaborate to establish local RAT manufacturing facility
Posted: 7 February 2022 Planet Innovation (PI), Australia’s leading healthtech innovation and commercialisation company, and Lumos Diagnostics (Lumos), a rapid point-of-care diagnostics company, with support from the Victorian State Government, will establish a $17.2 million Rapid Diagnostics Manufacturing…
Emerging Leaders Lab: Women in STEM pilot program – The Future of Work Lab at University of Melbourne
Posted: 2 February 2022 Do you identify as female and want to improve your leadership skills and learn to mentor? Are you 2 to 5 years out from your studies or currently completing a PhD in a STEM…
Cytiva fuels biotech development in Australia and New Zealand
Posted: 2 February 2022 VivaZome Therapeutics wins top prize with its potential to provide off-the-shelf regenerative medicines. Part of Cytiva’s BioChallenge global series, the inaugural challenge for the Australia and New Zealand region received 32 applications from various…
